Role of tyrosine kinase inhibitors in the treatment of pituitary tumours: from bench to bedside

scientific article published on 17 May 2017

Role of tyrosine kinase inhibitors in the treatment of pituitary tumours: from bench to bedside is …
instance of (P31):
review articleQ7318358
scholarly articleQ13442814

External links are
P356DOI10.1097/MED.0000000000000344
P932PMC publication ID5815830
P698PubMed publication ID28520590

P50authorOdelia CooperQ42659703
P2093author name stringAnat Ben-Shlomo
P2860cites workDifferential regulation of EGF receptor internalization and degradation by multiubiquitination within the kinase domainQ28119149
Mechanisms for pituitary tumorigenesis: the plastic pituitaryQ33630319
Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumorsQ33680681
Genomic characterization of human and rat prolactinomasQ34277575
ErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic miceQ34745279
HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy.Q34942996
Recurrent gain-of-function USP8 mutations in Cushing's diseaseQ35146226
EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomasQ35578652
The Gene of the Ubiquitin-Specific Protease 8 Is Frequently Mutated in Adenomas Causing Cushing's DiseaseQ35813265
Review on EGFR Inhibitors: Critical UpdatesQ35964161
Lack of Ubiquitin Specific Protease 8 (USP8) Mutations in Canine Corticotroph Pituitary AdenomasQ36231629
Expression and function of ErbB receptors and ligands in the pituitaryQ37135031
Heregulin regulates prolactinoma gene expressionQ37208143
Inhibition of Ubiquitin-specific Peptidase 8 Suppresses Adrenocorticotropic Hormone Production and Tumorous Corticotroph Cell Growth in AtT20 CellsQ37228518
Mutations in the deubiquitinase gene USP8 cause Cushing's diseaseQ41716700
UBPY-mediated epidermal growth factor receptor (EGFR) de-ubiquitination promotes EGFR degradationQ42833376
Synthesis and biological evaluation of 9-oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile analogues as potential inhibitors of deubiquitinating enzymesQ43148533
14-3-3-dependent inhibition of the deubiquitinating activity of UBPY and its cancellation in the M phase.Q53532387
Adrenocorticotropin-Producing Pituitary Carcinoma with Expression of c-erbB-2 and High PCNA Index: A Comparative Study with Pituitary Adenomas and Normal Pituitary TissuesQ74453740
The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing's diseaseQ86717911
P433issue4
P407language of work or nameEnglishQ1860
P304page(s)301-305
P577publication date2017-05-17
P1433published inCurrent Opinion in Endocrinology, Diabetes and ObesityQ15756285
P1476titleRole of tyrosine kinase inhibitors in the treatment of pituitary tumours: from bench to bedside
P478volume24

Reverse relations

cites work (P2860)
Q99545483Approach to the Treatment of a Patient with an Aggressive Pituitary Tumor
Q60921593Biomarker Discovery for Immunotherapy of Pituitary Adenomas: Enhanced Robustness and Prediction Ability by Modern Computational Tools
Q90139182Comparison of Radiographic Approaches to Assess Treatment Response in Pituitary Adenomas: Is RECIST or RANO Good Enough?
Q90111954Dopamine agonist resistant prolactinomas: any alternative medical treatment?
Q92210576Emerging and Novel Treatments for Pituitary Tumors
Q93063035Functioning Pituitary Adenomas - Current Treatment Options and Emerging Medical Therapies
Q49330862Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma).
Q55249109New Insights in Cushing Disease Treatment With Focus on a Derivative of Vitamin A.
Q47168700Relation among Aromatase P450 and Tumoral Growth in Human Prolactinomas

Search more.